DE60115054D1 - Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs - Google Patents

Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs

Info

Publication number
DE60115054D1
DE60115054D1 DE60115054T DE60115054T DE60115054D1 DE 60115054 D1 DE60115054 D1 DE 60115054D1 DE 60115054 T DE60115054 T DE 60115054T DE 60115054 T DE60115054 T DE 60115054T DE 60115054 D1 DE60115054 D1 DE 60115054D1
Authority
DE
Germany
Prior art keywords
treatment
cancer
trkaig2
prevention
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60115054T
Other languages
English (en)
Other versions
DE60115054T2 (de
Inventor
Shelley Jane Allen
David Dawbarn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Publication of DE60115054D1 publication Critical patent/DE60115054D1/de
Application granted granted Critical
Publication of DE60115054T2 publication Critical patent/DE60115054T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE60115054T 2000-08-18 2001-08-17 Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs Expired - Fee Related DE60115054T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0020504.7A GB0020504D0 (en) 2000-08-18 2000-08-18 Therapeutic method
GB0020504 2000-08-18
PCT/GB2001/003682 WO2002015924A1 (en) 2000-08-18 2001-08-17 Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer

Publications (2)

Publication Number Publication Date
DE60115054D1 true DE60115054D1 (de) 2005-12-22
DE60115054T2 DE60115054T2 (de) 2006-07-27

Family

ID=9897960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115054T Expired - Fee Related DE60115054T2 (de) 2000-08-18 2001-08-17 Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs

Country Status (10)

Country Link
US (2) US20040037831A1 (de)
EP (1) EP1309338B1 (de)
JP (1) JP2004506694A (de)
KR (1) KR20030040405A (de)
AT (1) ATE309817T1 (de)
AU (2) AU7862401A (de)
CA (1) CA2420051A1 (de)
DE (1) DE60115054T2 (de)
GB (1) GB0020504D0 (de)
WO (1) WO2002015924A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
US20030096753A1 (en) * 1998-04-09 2003-05-22 Robertson Alan George Simpson Therapeutic agent
GB0020504D0 (en) * 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
GB0122400D0 (en) * 2001-09-17 2001-11-07 Univ Bristol Polypeptide purification method
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
KR101080716B1 (ko) 2002-10-08 2011-11-07 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제를 투여함에 의한 수술-후 통증의치료방법 및 그를 함유하는 조성물
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2004073653A2 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
PT1732949E (pt) 2004-04-07 2010-03-23 Univ Minnesota Métodos de tratamento da dor associada ao cancro ósseo através da administração de um antagonista do factor de crescimento nervoso
US20090036380A1 (en) * 2006-03-14 2009-02-05 Yeda Research And Development Co., Ltd. Composition And Method For Brain Tumor Therapy
EP1857146A1 (de) * 2006-05-16 2007-11-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Respiratonsstörungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK166763C (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5789187A (en) * 1992-08-27 1998-08-04 Worcester Foundation For Experimental Biology Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6136581A (en) * 1996-11-22 2000-10-24 Sugen, Inc. Kinase genes and uses
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
US20030096753A1 (en) * 1998-04-09 2003-05-22 Robertson Alan George Simpson Therapeutic agent
GB0020504D0 (en) * 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
GB0122400D0 (en) * 2001-09-17 2001-11-07 Univ Bristol Polypeptide purification method

Also Published As

Publication number Publication date
AU7862401A (en) 2002-03-04
US20040037831A1 (en) 2004-02-26
US20070105773A1 (en) 2007-05-10
DE60115054T2 (de) 2006-07-27
GB0020504D0 (en) 2000-10-11
AU2001278624B2 (en) 2007-01-18
CA2420051A1 (en) 2002-02-28
WO2002015924A1 (en) 2002-02-28
EP1309338B1 (de) 2005-11-16
KR20030040405A (ko) 2003-05-22
EP1309338A1 (de) 2003-05-14
JP2004506694A (ja) 2004-03-04
ATE309817T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
ATE408601T1 (de) Fredericamycin-derivate
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
HUP0400782A2 (hu) Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
HUP0105281A2 (hu) Rákellenes hatású benzaldehidszármazékok és gyógyászati alkalmazásuk
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
HUP0401913A2 (hu) Bromhidrosis kezelésére és megelőzésére szolgáló gyógyszerkészítmény
PL368686A1 (en) Novel aminobenzoephenones
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee